Qiagen NV has reported its financial results for the period ending June 30, 2025. The company's net sales attributed to its country of domicile, the Netherlands, stood at $5.0 million for the three-month period and $10.6 million for the six-month period ending on the same date. This represents a slight increase compared to the $4.7 million and $9.5 million recorded in the respective periods of the previous year. In terms of earnings per share, basic EPS was reported at $0.44, while diluted EPS was also $0.44. A notable update in business operations includes the acquisition of GNX Data Systems Ltd., trading as Genoox, a privately held company based in Tel Aviv-Yafo, Israel. This acquisition, completed in May 2025, enhances Qiagen's capabilities with AI-powered software designed to scale and accelerate the processing of complex genetic tests. The acquisition is not deemed significant to the overall condensed consolidated financial statements. Further financial details and outlook were not disclosed in the release.